Capital Performance Advisors LLP Makes New $126,000 Investment in Natera, Inc. (NASDAQ:NTRA)

Capital Performance Advisors LLP acquired a new position in shares of Natera, Inc. (NASDAQ:NTRA) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund acquired 992 shares of the medical research company’s stock, valued at approximately $126,000.

A number of other large investors have also recently made changes to their positions in the stock. Vanguard Group Inc. lifted its position in Natera by 0.7% during the 1st quarter. Vanguard Group Inc. now owns 11,044,743 shares of the medical research company’s stock worth $1,010,152,000 after acquiring an additional 72,848 shares during the period. Farallon Capital Management LLC lifted its holdings in shares of Natera by 13.6% during the second quarter. Farallon Capital Management LLC now owns 4,460,557 shares of the medical research company’s stock worth $483,034,000 after purchasing an additional 532,874 shares during the period. Massachusetts Financial Services Co. MA boosted its position in Natera by 6.6% in the second quarter. Massachusetts Financial Services Co. MA now owns 2,397,582 shares of the medical research company’s stock valued at $259,634,000 after buying an additional 148,917 shares during the last quarter. Duquesne Family Office LLC increased its holdings in Natera by 2.4% in the 2nd quarter. Duquesne Family Office LLC now owns 1,974,880 shares of the medical research company’s stock worth $213,860,000 after buying an additional 45,500 shares during the period. Finally, Allspring Global Investments Holdings LLC raised its position in Natera by 25.0% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,229,558 shares of the medical research company’s stock worth $156,092,000 after buying an additional 246,246 shares during the last quarter. 99.90% of the stock is owned by hedge funds and other institutional investors.

Natera Price Performance

Shares of NASDAQ NTRA opened at $134.11 on Friday. The company has a debt-to-equity ratio of 0.34, a quick ratio of 4.01 and a current ratio of 4.14. The firm has a fifty day moving average of $124.35 and a 200 day moving average of $113.60. The firm has a market cap of $16.59 billion, a PE ratio of -54.74 and a beta of 1.53. Natera, Inc. has a one year low of $44.77 and a one year high of $134.33.

Natera (NASDAQ:NTRA) last issued its quarterly earnings results on Thursday, August 8th. The medical research company reported ($0.30) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.39. Natera had a negative net margin of 21.47% and a negative return on equity of 36.74%. The firm had revenue of $413.35 million for the quarter, compared to analyst estimates of $343.00 million. During the same period last year, the company posted ($0.97) EPS. Natera’s quarterly revenue was up 58.1% compared to the same quarter last year. As a group, research analysts predict that Natera, Inc. will post -1.96 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have recently commented on NTRA. Piper Sandler reaffirmed an “overweight” rating and issued a $150.00 price objective on shares of Natera in a report on Friday, September 13th. Stephens reaffirmed an “overweight” rating and set a $125.00 price target on shares of Natera in a research report on Friday, August 9th. UBS Group decreased their price objective on Natera from $160.00 to $145.00 and set a “buy” rating for the company in a report on Friday, August 9th. BTIG Research raised their target price on Natera from $125.00 to $135.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Finally, TD Cowen lifted their price target on Natera from $137.00 to $145.00 and gave the company a “buy” rating in a research report on Friday, August 9th. One analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $125.69.

Insider Buying and Selling at Natera

In other news, insider Jonathan Sheena sold 2,700 shares of Natera stock in a transaction that occurred on Monday, August 12th. The stock was sold at an average price of $113.82, for a total value of $307,314.00. Following the sale, the insider now directly owns 299,441 shares of the company’s stock, valued at $34,082,374.62. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other news, insider Jonathan Sheena sold 2,700 shares of the stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $113.82, for a total value of $307,314.00. Following the completion of the sale, the insider now directly owns 299,441 shares in the company, valued at $34,082,374.62. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Michael Burkes Brophy sold 1,866 shares of the firm’s stock in a transaction dated Thursday, October 31st. The stock was sold at an average price of $126.45, for a total transaction of $235,955.70. Following the completion of the transaction, the chief financial officer now directly owns 68,851 shares in the company, valued at approximately $8,706,208.95. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 50,164 shares of company stock valued at $6,157,291 over the last quarter. 7.60% of the stock is currently owned by insiders.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.